<DOC>
	<DOCNO>NCT00102219</DOCNO>
	<brief_summary>This non-randomized Phase 2 study test pemetrexed doxorubicin combination locally advance metastatic breast cancer . Both pemetrexed doxorubicin combine drug , yet combine . It expect patient benefit different mechanism action two drug . However , guarantee patient benefit treatment .</brief_summary>
	<brief_title>A Study Pemetrexed Plus Doxorubicin Given Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis locally advance metastatic breast cancer amenable local treatment . Patients must chemonaive receive neoadjuvant and/or adjuvant chemotherapy . At least one measurable lesion . No chemotherapy within 4 week prior enrollment . Signed informed consent patient . Prior chemotherapy metastatic breast cancer . Prior treatment anthracyclines anthracenedionecontaining regimen . Treatment within last 30 day drug receive regulatory approval . Pregnancy and/or breast feeding . Inability unwillingness take folic acid vitamin B12 supplementation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>